Laurel Wealth Planning’s AbbVie ABBV Stock Holding History

Laurel Wealth Planning’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+803	New	+$173K	0.09%	66
2026 Q1	–	Sell	-1,031	Closed	-$236K	–	60
2025 Q4	$236K	Buy	+1,031	New	+$235K	0.13%	54
2025 Q3	–	Sell	-1,128	Closed	-$209K	–	58
2025 Q2	$209K	Hold	1,128	–	–	0.12%	55
2025 Q1	$236K	Hold	1,128	–	–	0.16%	49
2024 Q4	$200K	Hold	1,128	–	–	0.13%	54
2024 Q3	$223K	Buy	+1,128	New	+$211K	0.15%	52
2024 Q2	–	Sell	-1,128	Closed	-$205K	–	52
2024 Q1	$205K	Buy	+1,128	New	+$194K	0.14%	53
2023 Q2	–	Sell	-1,285	Closed	-$205K	–	55
2023 Q1	$205K	Sell	1,285 -147	-10%	-$22.5K	0.14%	57
2022 Q4	$231K	Hold	1,432	–	–	0.15%	56
2022 Q3	$192K	Hold	1,432	–	–	0.14%	56
2022 Q2	$219K	Sell	1,432 -225	-14%	-$34.4K	0.15%	56
2022 Q1	$269K	Buy	1,657 +1,500	+955%	+$218K	0.18%	63
2021 Q4	$21K	Hold	157	–	–	0.02%	113
2021 Q3	$17K	Buy	157 +100	+175%	+$11.4K	0.01%	117
2021 Q2	$6K	Hold	57	–	–	0.01%	104
2021 Q1	$6K	Hold	57	–	–	0.01%	98
2020 Q4	$6K	Buy	+57	New	+$5.48K	0.01%	91

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Laurel Wealth Planning's ABBV Position: Q2 2026 in Review

Laurel Wealth Planning opened a new position in AbbVie (ABBV) in Q2 2026: 803 shares worth $202K. The stake represents 0.09% of the portfolio and ranks #66 among its holdings. This is a return to the name: Laurel Wealth Planning previously reported a position in ABBV as recently as Q4 2025.

Laurel Wealth Planning first reported a position in ABBV in Q4 2020 and has held it in 17 quarters since. The position peaked at $269K in Q1 2022. 4,217 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Laurel Wealth Planning held 803 shares of AbbVie worth $202K as of Q2 2026.
AbbVie was a new Laurel Wealth Planning position in Q2 2026.
AbbVie made up 0.09% of Laurel Wealth Planning's portfolio in Q2 2026, its #66 holding.
Laurel Wealth Planning first reported a position in AbbVie in Q4 2020 and has held it in 17 quarters since.
Laurel Wealth Planning's AbbVie position peaked at $269K in Q1 2022.
4,217 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Laurel Wealth Planning's 13F filing for Q2 2026, filed 30 Jul 2026.